2022 ESMO大会即将于9月9日（欧洲中部夏令时间，CEST）在法国首都巴黎凡尔赛门展览馆开幕。
日前，含LBA在内的大会日程安排均已公布，「肿瘤资讯」整理了会上将进行报告的乳腺癌、妇瘤、头颈部肿瘤研究，供参考。
Proffered Paper session
LBA13：纳武利尤单抗联和伊匹木单抗治疗具有肿瘤浸润淋巴细胞的早期三阴性乳腺癌：BELLINI试验的首次结果
原标题：Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial
报告专家：Iris Nederlof (Amsterdam, Netherlands)
LBA14：年龄、复发评分和卵巢功能抑制对术前短期内分泌治疗效果的影响：ADAPT和 ADAPTcycle 试验分析
原标题：Impact of age, Recurrence Score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials
报告专家：Oleg Gluz (Mönchengladbach, Germany)
LBA15：MONARCH 3：在HR+/HER2- 晚期乳腺癌患者中联合阿贝西利和非甾体类芳香化酶抑制剂治疗的中期总生存期结果
原标题：MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
报告专家：Matthew P. Goetz (Rochester, United States of America)
LBA16：达尔西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌 (DAWNA-2)：一项 III 期试验
原标题：Dalpiciclib plus letrozole or anastrozole as 1st-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): a phase 3 trial
报告专家：徐兵河 (北京, 中国)
LBA17：一线化疗-免疫治疗的随机II期SYNERGY试验的主要终点结果：采用度伐利尤单抗、紫杉醇和卡铂联合或不联合抗CD73抗体oleclumab治疗晚期或转移性三阴性乳腺癌
原标题：Primary endpoint results of SYNERGY, a randomized phase 2 trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
报告专家：Laurence Buisseret (Brussels, Belgium)
LBA76：III期TROPiCS-02研究：在HR +/HER2-转移性乳腺癌患者中比较戈沙妥珠单抗与医生选择性治疗的总生存期结果
原标题： Overall survival (OS) results from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
报告专家：Hope S. Rugo (San Francisco, United States of America)
Mini Oral session
LBA18：在HR+/HER2+ 晚期乳腺癌患者中比较阿贝西利+ 曲妥珠单抗 +/-氟维司群与曲妥珠单抗 + 化疗的最终总生存期 (monarcHER) ：一项随机、开放标签的II期试验
原标题：Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial
报告专家：Fabrice André (Villejuif, France)
LBA19：吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗 HER2+转移性乳腺癌 (PHILA)：一项随机 III 期试验
原标题： Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase 3 trial
报告专家：徐兵河 (北京, 中国)
LBA20：一项在ER+/HER2-、出现雌激素受体1突变、经过芳香化酶和CDK4/6抑制剂治疗后疾病进展的局部晚期/转移性乳腺癌患者中比较lasofoxifene与氟维司群的开放标签的随机化研究
原标题：Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
报告专家：Matthew P. Goetz (Rochester, United States of America)
Proffered Paper session
LBA29：评价奥拉帕利 + 贝伐珠单抗维持治疗新诊断晚期卵巢癌患者的 III 期 PAOLA-1/ENGOT-ov25 试验的最终总生存期结果
原标题：Final overall survival (OS) results from the Phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
报告专家：Isabelle L. Ray-Coquard (Lyon, France)
LBA30：III 期 ATALANTE/ov29 试验：在含铂化疗联合贝伐珠单抗治疗对铂敏感复发上皮性卵巢癌患者中，比较阿替利珠单抗和安慰剂的疗效
原标题：Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
报告专家：Jean Emmanuel Kurtz (Strasbourg, France)
LBA31：随机III期GOTIC-002 LUFT试验：替加氟-尿嘧啶维持化疗与观察后同步放化疗在局部晚期宫颈癌的比较
原标题：Randomized phase 3 trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial
报告专家：Keiichi Fujiwara (Saitama, Japan)
Mini Oral session
LBA32: GX-188E（一种治疗性 DNA 疫苗）联合帕博利珠单抗治疗 HPV 16 和/或 18 阳性晚期宫颈癌（II 期）的疗效和安全性：对 PD-L1 阳性和阴性患者均安全有效
原标题：Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (Phase II): Safe and effective in both PD-L1 positive and negative
报告专家：Sungjong Lee (Seoul, Korea, Republic of)
Proffered Paper session& Presidential Symposium II
LBA5：III期KEYNOTE-412研究的初步结果：帕博利珠单抗联合放化疗对比安慰剂联合放化疗治疗局部晚期头颈部鳞状细胞癌
原标题：Primary results of the phase 3 KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
报告专家：Jean-Pascal Machiels (Woluwe-Saint-Lambert, Belgium)
Mini Oral session
LBA33：局部晚期头颈部鳞状细胞癌患者接受xevinapant + 放化疗 vs 安慰剂 +放化疗治疗的5年总生存期：一项II期随机化研究
原标题：5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase 2 study
报告专家：Jean Bourhis (Lausanne, Switzerland)
排版编辑：肿瘤资讯-Paine
苏公网安备32059002004080号
